Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin vs. Docetaxel-Cetuximab with IMRT in Locally Advanced HNSCC
NCT02128906Phase 2Recruiting
- Start
- Dec 2013
- Primary completion
- Dec 2031
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, docetaxel, cetuximab in head and neck squamous cell carcinoma (HNSCC). Started Dec 2013; status: recruiting.
02
Drugs
cisplatindocetaxelcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02128906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128906.